• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    CeriBell Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    1/2/26 4:45:27 PM ET
    $CBLL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $CBLL alert in real time by email
    8-K
    0001861107false00018611072025-12-302025-12-30

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): December 30, 2025

     

     

    CeriBell, Inc.

    (Exact name of Registrant as Specified in Its Charter)

     

     

    Delaware

    001-42364

    47-1785452

    (State or Other Jurisdiction
    of Incorporation)

    (Commission File Number)

    (IRS Employer
    Identification No.)

     

     

     

     

     

    360 N. Pastoria Avenue

     

    Sunnyvale, California

     

    94085

    (Address of Principal Executive Offices)

     

    (Zip Code)

     

    Registrant’s Telephone Number, Including Area Code: 800 436-0826

     

     

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:


    Title of each class

     

    Trading
    Symbol(s)

     


    Name of each exchange on which registered

    Common stock, $0.001 par value per share

     

    CBLL

     

    Nasdaq Global Select Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     


    Item 5.02

    Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

     

    On December 30, 2025, Lucian Iancovici notified the Board of Directors (the “Board”) of CeriBell, Inc. (the “Company”) of his resignation from the Board and from his positions as Chair of the Nominating and Corporate Governance Committee and as a member of the Compensation Committee, effective as of December 31, 2025. The resignation did not result from any disagreement with the Company on any matter relating to its operations, policies, or practices.

    Item 9.01

    Financial Statements and Exhibits.

     

    Exhibit No.

    Description

    99.1

    Resignation Letter dated December 30, 2025.

    104

    Cover Page Interactive Data File, formatted in Inline XBRL.

     

     


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

     

    CERIBELL, INC.

     

     

     

     

    Date:

    January 2, 2026

    By:

    /s/ Scott Blumberg

     

     

     

    Scott Blumberg
    Chief Financial Officer

     


    Get the next $CBLL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CBLL

    DatePrice TargetRatingAnalyst
    10/21/2025$19.00Strong Buy
    Raymond James
    6/24/2025$30.00Buy
    BTIG Research
    4/4/2025$32.00Buy
    Ladenburg Thalmann
    11/5/2024$32.00Buy
    BofA Securities
    11/5/2024$30.00Buy
    Canaccord Genuity
    11/5/2024$32.00Overweight
    JP Morgan
    11/5/2024$31.00Buy
    TD Cowen
    11/5/2024Outperform
    William Blair
    More analyst ratings

    $CBLL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Tpg Gp A, Llc converted options into 3,587,154 shares and bought $6,464,556 worth of shares (380,268 units at $17.00) (SEC Form 4)

    4 - Ceribell, Inc. (0001861107) (Issuer)

    10/17/24 4:14:38 PM ET
    $CBLL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Tammenoms Bakker Juliet was granted 6,618 shares, converted options into 2,140,600 shares and bought $4,032,978 worth of shares (237,234 units at $17.00) (SEC Form 4)

    4 - Ceribell, Inc. (0001861107) (Issuer)

    10/16/24 4:18:06 PM ET
    $CBLL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $CBLL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Technology Officer Woo Raymond exercised 11,112 shares at a strike of $4.37, sold $235,382 worth of shares (11,112 units at $21.18) and covered exercise/tax liability with 687 shares, decreasing direct ownership by 0.41% to 167,317 units (SEC Form 4)

    4 - Ceribell, Inc. (0001861107) (Issuer)

    1/6/26 5:16:43 PM ET
    $CBLL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Robertson Rebecca B sold $54,725 worth of shares (2,500 units at $21.89) and exercised 2,500 shares at a strike of $2.24 (SEC Form 4)

    4 - Ceribell, Inc. (0001861107) (Issuer)

    1/6/26 5:16:09 PM ET
    $CBLL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: Director Robertson Rebecca B sold $131,255 worth of shares (7,445 units at $17.63), decreasing direct ownership by 26% to 21,230 units (SEC Form 4)

    4/A - Ceribell, Inc. (0001861107) (Issuer)

    1/6/26 5:15:47 PM ET
    $CBLL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $CBLL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Ceribell Receives FDA Breakthrough Device Designation for LVO Stroke Detection and Monitoring Solution

    SUNNYVALE, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (NASDAQ:CBLL) ("Ceribell"), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for its Large Vessel Occlusion (LVO) stroke detection monitor for patients in the hospital setting. This first-in-class LVO stroke detection monitor uses Ceribell's existing hardware and applies an AI-based algorithm to interpret EEG signals for early detection of LVO stroke. The Breakthrough Device Designation for LVO Stroke represents the latest achievemen

    1/5/26 8:00:00 AM ET
    $CBLL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Ceribell to Participate in the 44th Annual J.P. Morgan Healthcare Conference

    SUNNYVALE, Calif., Dec. 30, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (NASDAQ:CBLL) ("Ceribell"), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that Jane Chao, Ph.D., CEO and Co-founder, will present at the upcoming 44th Annual J.P. Morgan Healthcare Conference in San Francisco. The presentation will take place on Monday, January 12, 2026, at 9:00 am Pacific Standard Time / 12:00 pm Eastern Standard Time.  Event: 44th Annual J.P. Morgan Healthcare ConferenceDate: Monday, January 12, 2026Time: 9:00 am PST / 12:00 pm EST A live and archived webcast of the presentation will be available in th

    12/30/25 4:05:00 PM ET
    $CBLL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    AI Diagnostics Hit Critical Mass as Hospitals Race to Cut Costs

    ISSUED ON BEHALF OF VENTRIPOINT DIAGNOSTICS LTD. VANCOUVER, BC, Dec. 12, 2025 /PRNewswire/ -- USANewsGroup.com News Commentary – Point-of-care infectious disease diagnostics valued at $53 billion in 2024 are projected to nearly double by 2033, driven by AI systems that deliver laboratory-grade results at the bedside[1]. Meanwhile, healthcare organizations implementing domain-specific AI tools surged 7x in 2025 as financial pressure mounts, with hospital expenses rising 6% annually while revenue grows just 3%[2]. Five publicly traded companies are positioned at the center of this shift, each holding FDA clearance for AI systems that eliminate diagnostic delays and transform patient management

    12/12/25 9:49:00 AM ET
    $ABT
    $CBLL
    $HTFL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Medical/Dental Instruments

    $CBLL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Raymond James initiated coverage on CeriBell with a new price target

    Raymond James initiated coverage of CeriBell with a rating of Strong Buy and set a new price target of $19.00

    10/21/25 7:19:41 AM ET
    $CBLL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    BTIG Research initiated coverage on CeriBell with a new price target

    BTIG Research initiated coverage of CeriBell with a rating of Buy and set a new price target of $30.00

    6/24/25 8:00:31 AM ET
    $CBLL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Ladenburg Thalmann initiated coverage on CeriBell with a new price target

    Ladenburg Thalmann initiated coverage of CeriBell with a rating of Buy and set a new price target of $32.00

    4/4/25 8:27:23 AM ET
    $CBLL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $CBLL
    SEC Filings

    View All

    CeriBell Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Ceribell, Inc. (0001861107) (Filer)

    1/5/26 10:53:59 AM ET
    $CBLL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    CeriBell Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - Ceribell, Inc. (0001861107) (Filer)

    1/2/26 4:45:27 PM ET
    $CBLL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 144 filed by CeriBell Inc.

    144 - Ceribell, Inc. (0001861107) (Subject)

    1/2/26 11:21:26 AM ET
    $CBLL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $CBLL
    Leadership Updates

    Live Leadership Updates

    View All

    Medtech Leader Erica Rogers Joins Ceribell Board of Directors

    SUNNYVALE, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (NASDAQ:CBLL) ("Ceribell" or the "Company"), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced the appointment of Erica Rogers to its Board of Directors. Ms. Rogers brings over three decades of experience leading high-growth, innovative medical device companies to Ceribell's Board as the Company executes on its mission to expand patient access to timely brain monitoring in the acute care setting. Ms. Rogers is an accomplished healthcare executive with board experience in both the public and private sectors. She most recently

    9/22/25 8:00:03 AM ET
    $CBLL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Ceribell Appoints Kristie Rodenbush as Chief People Officer and Brian Price as Senior Vice President of Marketing

    —Ms. Rodenbush to lead hiring and talent development initiatives— —Mr. Price to focus on market development and penetration— SUNNYVALE, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- CeriBell, Inc. (NASDAQ:CBLL), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions ("Ceribell"), today announced the appointments of Kristie Rodenbush as Chief People Officer and Brian Price as Senior Vice President of Marketing to its leadership team. "Ms. Rodenbush and Mr. Price bring an impressive wealth of experience to Ceribell, and I am confident that their leadership across our People & Culture and Marketing fu

    11/19/24 8:00:00 AM ET
    $CBLL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $CBLL
    Financials

    Live finance-specific insights

    View All

    Ceribell Reports Third Quarter 2025 Financial Results

    SUNNYVALE, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (NASDAQ:CBLL) ("Ceribell"), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today reported financial results for the quarter ended September 30, 2025. Third Quarter 2025 & Recent Highlights Reported total revenue of $22.6 million in the third quarter of 2025, a 31% increase compared to the same period in 2024Achieved gross margin of 88% compared to 87% for the same period in 2024 Ended the quarter with 615 total active accounts Appointed Erica Rogers to the Board of Directors "We are encouraged by our third quarter performance, which re

    11/4/25 4:05:00 PM ET
    $CBLL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Ceribell to Report Third Quarter 2025 Financial Results on November 4, 2025

    SUNNYVALE, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (NASDAQ:CBLL) ("Ceribell"), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that it will release financial results for the third quarter of 2025 after the close of trading on Tuesday, November 4, 2025. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET on November 4, 2025. Investors interested in listening to the conference call may do so by dialing (800) 715-9871 for domestic callers or (646) 307-1963 for international callers and providing access code 93946

    10/21/25 4:05:00 PM ET
    $CBLL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Ceribell Reports Second Quarter 2025 Financial Results

    SUNNYVALE, Calif., Aug. 05, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (NASDAQ:CBLL) ("Ceribell"), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today reported financial results for the quarter ended June 30, 2025. Second Quarter 2025 & Recent Highlights Reported total revenue of $21.2 million in the second quarter of 2025, a 38% increase compared to the same period in 2024Achieved gross margin of 88% in the second quarter of 2025Ended the quarter with 584 total active accounts  "We are pleased with our second quarter results, which reflect our successful commercial execution as we accelerate adopt

    8/5/25 4:05:00 PM ET
    $CBLL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $CBLL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by CeriBell Inc.

    SC 13G - Ceribell, Inc. (0001861107) (Subject)

    11/7/24 9:24:55 AM ET
    $CBLL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13D filed by CeriBell Inc.

    SC 13D - Ceribell, Inc. (0001861107) (Subject)

    10/22/24 4:20:26 PM ET
    $CBLL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care